Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
Published online: 21 March 2023
K. Fizazi & S. Gillessen, et al., on behalf of the ESMO Guidelines Committee
- Abiraterone acetate with prednisone improved MFS and OS for very-high-risk localised prostate cancer undergoing RT and ADT.
- Combining ADT with docetaxel–abiraterone–prednisone in men with de novo mHSPC improved both rPFS and OS versus ADT–docetaxel.
- Combining ADT with docetaxel and darolutamide in men with mHSPC improved OS versus ADT–docetaxel.
- Olaparib improved OS in men with mCRPC and BRCA alterations post-novel androgen receptor axis inhibitor.
- Cabazitaxel in men with mCRPC post-novel androgen receptor axis inhibitor and docetaxel improved both rPFS and OS.
- 177Lu-PSMA-617 in men with mCRPC post-novel androgen receptor axis inhibitor and taxanes improved both rPFS and OS.